Item 7.01 Regulation FD Disclosure.
On October 8, 2021, Repare Therapeutics Inc. (the "Company"), issued a press
release announcing initial Phase 1 monotherapy clinical data from its ongoing
Phase 1/2 TRESR clinical trial of RP-3500. As described in the press release,
the Company will present the initial Phase 1 monotherapy clinical data from the
ongoing Phase 1/2 TRESR clinical trial at the AACR-NCI-EORTC Virtual
International Conference on Molecular Targets and Cancer Therapeutics on
October 8, 2021. In addition, at 5:00 p.m. Eastern Time on October 8, 2021,
following the AACR-NCI-EORTC oral presentation, the Company will host a virtual
investor webcast where members of the Company's management team will present
further details regarding the Phase 1/2 TRESR clinical trial. The virtual event
and related materials can be accessed via the News and Events section of the
Company's website and will be available for 90 days following the event. A copy
of the press release is furnished as Exhibit 99.1 to this Current Report and
incorporated herein by reference.
The information under this Item 7.01, including Exhibit 99.1 attached hereto, is
intended to be furnished and shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended, or the Exchange Act, except as expressly set forth by specific
reference in such filing.
Item 9.01 Financial Statements and Exhibit.
(d) Exhibits
Exhibit
No. Description
99.1 Press release dated October 8, 2021.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses